Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burke, R. E.
Right arrow Articles by Willner, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burke, R. E.
Right arrow Articles by Willner, J. H.
NEUROLOGY 1981;31:1022
© 1981 American Academy of Neurology

Neuroleptic Malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease

Robert E. Burke, Stanley Fahn, Richard Mayeux, Harold Weinberg, Kenneth Louis and Joseph H. Willner

Neurological Institute, Columbia-Presbyterian Medical Center, New York, NY.

Address correspondence and reprint requests to Dr. Burke, Neurological Institute, Dept of Neurology, 710 W. 168 Street, New York, NY 10032.

Prior reports of neuroleptic malignant syndrome (NMS) concerned patients with psychiatric disorders, usually schizophrenia, who were taking dopamine receptor blocking agents. We report the syndrome in a patient with Huntington disease who was treated with dopamine-depleting agents. He had a negative evaluation for malignant hyperthermia (MH), and we suggest that NMS differs from MH. The occurrence of NMS caused by dopamine-depleting agents suggests that anticholinergic properties of phenotiazines are not the only cause. Central dopaminergic systems probably participate in thermo-regulation, and dopamine depletion probably plays a pathogenetic role in this syndrome.




This article has been cited by other articles:


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
R. Ankenman and M. F. Salvatore
Low Dose Alpha-Methyl-Para-Tyrosine (AMPT) in the Treatment of Dystonia and Dyskinesia
J Neuropsychiatry Clin Neurosci, February 1, 2007; 19(1): 65 - 69.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
P. Adnet, P. Lestavel, and R. Krivosic-Horber
Neuroleptic malignant syndrome
Br. J. Anaesth., July 1, 2000; 85(1): 129 - 135.
[Full Text] [PDF]


Home page
BMJHome page
P M Haddad
Neuroleptic malignant syndrome: May be caused by other drugs..
BMJ, January 15, 1994; 308(6922): 200 - 200.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by AAN Enterprises, Inc.